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The promise of a stem/progenitor cell-mediated cardiac repair
after myocardial infarction (MI) has fascinated basic scientists and
clinical cardiologists alike, and initial small- and intermediate-scale
clinical studies have examined the effects of a single intracoronary
administration of unfractionated or mononuclear bone marrow
cells (BMCs) on left ventricular (LV) function in patients after MI.
Several recent meta-analyses of these controlled clinical studies
have suggested a moderate, but significant, improvement of LV
ejection fraction (EF) by BMC therapy in patients after MI.1,2 The
most recent meta-analysis by Martin-Rendon et al. reported an
improvement in LVEF of 2.99% in patients undergoing BMC
therapy after MI.2 This was close to the observed improvement
in LVEF of 2.5% in the REPAIR-AMI (Remodeling in Acute Myocar-
dial Infarction) trial, the largest randomized, controlled clinical
study of BMC therapy in patients after MI.3 Although these poten-
tial effects of BMC therapy on LV function are less than many
investigators were hoping for, it should be noted that several of
our established clinical therapies with an impact on prognosis in
patients with MI and a reduced LV function, such as angiotesin-
converting enzyme (ACE) inhibitor or b-blocker therapy, are
associated with similar improvements in LVEF4 and have been
observed in patients after MI with a less optimal background
therapy as compared with present studies. There are, however,
many remaining open questions with respect to mechanisms of
stem/progenitor cell therapy after MI and potential strategies to
optimize its effects.
To date, BMCs have either been used unfractionated or as mono-
nuclear cells in clinical studies in patients after MI. This clearly
represents a heterogenous population of cells, so that it remains
unclear which of the cells is particularly important for the potential
effects on cardiac repair. Tendera et al. now report the results of the
REGENT trial (Myocardial Regeneration by Intracoronary Infusion of
Selected Population of Stem Cells in Acute Myocardial Infarction), a
multicentre study comparing the effect of unselected mononuclear
BMCs with an 100 times lower number of selected CD34þ/
CXCR4þ mononuclear BMCs in patients after MI.5 The rationale
for selecting CD34þ/CXCR4þ cells was based on the observation
from clinical studies that these cells are mobilized from the bone
marrow in response to myocardial ischaemia6 and from experimen-
tal studies indicating that these cells may express endothelial and
cardiac lineage markers.7
Although 200 patients were randomized to intracoronary infusion
of unselected (n ¼ 80) or selected (n ¼ 80)mononuclear BMCsor to
the control group (n ¼ 40) without BMC therapy, the primary end-
point of the study was evaluated in 117 patients, i.e. in 58.5% of the
patients included the study. The primary endpoint was defined as
change of LVEF and volumes as measured by magnetic resonance
imaging (MRI) before and 6 months after the procedure. In the
single analysis of each cell therapy group, LVEF increased significantly
by 3%, which was not observed in the control group; however, the
absolute differences between the groups did not reach statistical sig-
nificance after Bonferroni correction. A possible explanation for the
lack of a significant difference between the groups may be a reduced
power of the study, due to the analysis of the primary endpoint in
,60% of the patients and a smaller change in LVEF after BMC
therapy than expected when the study was planned (expected
change of LVEF .5%). This may be supported by the observation
that the magnitude of the change of LVEF in the cell therapy groups
corresponds well to what has been reported in the above
meta-analyses and the largest published randomized study in the
field, the REPAIR-AMI trial.3 We have therefore to interpret the
results of the REGENT trial with caution, since a limited power of
the studymay have prevented the authors being able to show a signifi-
cant difference for the primary endpoint, as has been pointed out by
the authors themselves.
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Interestingly, the analysis of potential factors favouring the effect
of BMC therapy on LV function in the REGENT trial revealed that
a significant increase of LVEF was only observed in patients treated
with BMCs who had a baseline LVEF below the median (i.e. LVEF
,37%). This corresponds well to the observation in the REPAIR-
AMI study that patients with a lower baseline LVEF derived most
benefit.3 Therefore, these analyses are generating the hypothesis
that selecting patients with a severe impairment of LVEF after MI
may be one way to increase the benefit of this therapy.
The study design of Tendera et al. did not compare similar
numbers of unselected and selected BMCs (the number of
selected BMCs was 100 times lower), and the ‘selected’ cells
remained contained in the unselected BMCs.5 Such a selection of
subfractions of BMCs would be expected to augment the effect
of cell therapy on cardiac function only when there are other
cell fractions within BMCs that would exert an inhibitory effect
on cardiac repair, which remains largely unkown at present.
However, a similar increase of LVEF with unselected cells and
selected cells of a substantially lower number would argue for an
important role for the selected cell population in the effects on
cardiac function.
The mechanisms by which BMC therapy may improve cardiac
function are still debated and not entirely clear. Whereas initial
experimental studies had suggested a rapid transdifferentiation of
BMCs (c-kitþ, lineage–) into cardiomyocytes after cardiac injection
post-MI,8 probably inspired by the concept of a high stem cell plas-
ticity of adult stem cells, later experimental studies using genetic
techniques to follow bone marrow cell fate reported that transdif-
ferentiation of BMCs into cardiomyocytes did not explain the
observed effects of BMCs on LV function,9 and suggested that
BMCs act rather by paracrine mechanisms to improve cardiac func-
tion, such as by stimulation of capillary growth, prevention of car-
diomyocyte apoptosis or stimulation of resident cardiac stem
cells.10,11 In fact, inhibition of endogenous mobilization of stem
cells from bone marrow after experimental MI augmented myocar-
dial damage after MI and resulted in an impaired capillary growth in
the infarct border zone.11 The debate of the concept of stem cell
plasticity, i.e. whether adult stem cells in addition to pluripotent
stem cells can transdifferentiate into non-organ-specific cell
types, is not unique to the cardiovascular field. Similarly, several
groups had observed that adult BMCs repaired damaged liver
tissue, which was initially suggested to result from transdifferentia-
tion into liver cells, but later was reported to be a consequence of
cell fusion with liver cells.12 Cell fusion has also been suggested to
explain in part the discrepant findings with respect to the transdif-
ferentiation potential of BMCs into cardiomyocytes.13 Whether
strategies to enhance cardiomyogenic differentiation of adult
stem/progenitor cells, i.e. by activation of cardiogenic Wnt path-
ways14 or by small molecules,15 or whether induction of pluripo-
tency16 will be required to enhance cardiomyogenesis efficiently
remains one of the important future challenges.
While the initially perceived rapid chance for a complete cardiac
repair by stem/progenitor cell therapy after MI has generated high
expectations, now the potential of this therapy needs to be care-
fully developed by addressing important remaining questions,
including the optimal cell types and pre-conditioning, the timing
and dosing of cells to be used, how to augment the functional
repair capacity of transplanted cells, how to optimize their
homing and engraftment in the heart, and how to select the
patients that may benefit most from this therapy. An important
focus of present basic and clinical studies is therefore directed
towards optimizing the outcome and effect of stem/progenitor
cell-based therapies, such as by improving stem/progenitor cell
repair capacity and the process of cardiac cell homing. Notably,
the vascular and pro-angiogenic repair capacity of autologous
stem/progenitor cells is reduced by cardiovascular risk factors,
such as diabetes,17 and by ageing, probably representing an impor-
tant potential target for optimization of cell-based therapy. A
reduced nitric oxide (NO) production by both circulating and
bone marrow-derived stem/progenitor cells has been suggested
to be critical for their reduced in vivo repair capacity.17,18 Augmen-
ted expression of endothelial NO synthase by gene transfer into
endothelial progenitor cells prior to cardiac transplantation is cur-
rently being explored in the clinical ENACT-AMI trial as a strategy
to augment cell repair capacity. Furthermore, several strategies are
examined to improve homing and engraftment of mobilized stem/
progenitor cells,19 i.e. the SITAGRAMI trial. Moreover, the timing
and dosing of cell transplantation may be relevant for the effect
of BMC therapy after MI, which is currently being examined in
the SWISS-AMI and BOOST-2 trials.
Whereas the present clinical studies of BMC therapy have
largely examined the effect on LVEF, i.e. a surrogate endpoint, ulti-
mately the validation of cardiac cell therapy for clinical use will
depend on the demonstration of a benefit with regard to clinical
outcomes, similar to reperfusion therapy. In this respect, besides
optimizing the conditions of cell therapy, selection of the patients
who may benefit most from this therapy, i.e. based on LVEF and
other parameters, will probably be an important issue to
examine adequately the clinical potential of this novel therapeutic
concept.
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